{
  "actions": [
    {
      "acted_at": "2025-02-06",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2025-02-06",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the House Committee on Energy and Commerce.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr1051-119",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "Referred To"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    }
  ],
  "congress": "119",
  "cosponsors": [],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2025-02-06",
  "number": "1051",
  "official_title": "To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.",
  "popular_title": null,
  "related_bills": [],
  "short_title": null,
  "sponsor": {
    "bioguide_id": "B001315",
    "district": "13",
    "name": "Budzinski, Nikki",
    "state": "IL",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2025-02-06",
  "subjects": [
    "Drug safety, medical device, and laboratory regulation",
    "Health",
    "Prescription drugs"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2025-02-06",
    "date": "2025-06-09T17:57:34Z",
    "text": ""
  },
  "titles": [
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.",
      "type": "official"
    },
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.",
      "type": "display"
    }
  ],
  "updated_at": "2025-06-09T17:58:46Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/119/hr/BILLSTATUS-119hr1051.xml"
}